"Imugene Limited (ASX: IMU), a clinical-stage immunooncology company, advises that the Board will seek shareholder approval at an upcoming Extraordinary General Meeting (EGM), expected to be held in June 2025, to consolidate the issued share capital of the Company at a ratio of 1 security for every 34 securities currently held (Consolidation)."
IMU Price at posting:
2.2¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)